CA3136216C - Method of treating tumours - Google Patents

Method of treating tumours Download PDF

Info

Publication number
CA3136216C
CA3136216C CA3136216A CA3136216A CA3136216C CA 3136216 C CA3136216 C CA 3136216C CA 3136216 A CA3136216 A CA 3136216A CA 3136216 A CA3136216 A CA 3136216A CA 3136216 C CA3136216 C CA 3136216C
Authority
CA
Canada
Prior art keywords
compound
tumour
epoxy
hexahydroxy
tiglien
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3136216A
Other languages
English (en)
French (fr)
Other versions
CA3136216A1 (en
Inventor
Victoria Anne Gordon
Paul Warren Reddell
Glen Mathew BOYLE
Jason Kingsley CULLEN
Peter Gordon Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QBiotics Pty Ltd
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019901280A external-priority patent/AU2019901280A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Publication of CA3136216A1 publication Critical patent/CA3136216A1/en
Application granted granted Critical
Publication of CA3136216C publication Critical patent/CA3136216C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3136216A 2019-04-12 2020-04-09 Method of treating tumours Active CA3136216C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019901280 2019-04-12
AU2019901280A AU2019901280A0 (en) 2019-04-12 Method of Treatment
PCT/AU2020/050360 WO2020206504A1 (en) 2019-04-12 2020-04-09 Method of treating tumours

Publications (2)

Publication Number Publication Date
CA3136216A1 CA3136216A1 (en) 2020-10-15
CA3136216C true CA3136216C (en) 2024-01-16

Family

ID=72752169

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3136216A Active CA3136216C (en) 2019-04-12 2020-04-09 Method of treating tumours

Country Status (26)

Country Link
US (1) US12226391B2 (https=)
EP (1) EP3952858B1 (https=)
JP (2) JP2022528915A (https=)
KR (1) KR20210152531A (https=)
CN (1) CN113924091A (https=)
AU (1) AU2020256847B2 (https=)
BR (1) BR112021020253A2 (https=)
CA (1) CA3136216C (https=)
DK (1) DK3952858T3 (https=)
EA (1) EA202192757A1 (https=)
ES (1) ES3063750T3 (https=)
FI (1) FI3952858T3 (https=)
HR (1) HRP20260232T1 (https=)
IL (1) IL287210B2 (https=)
LT (1) LT3952858T (https=)
MX (1) MX2021012449A (https=)
MY (1) MY208979A (https=)
PL (1) PL3952858T3 (https=)
PT (1) PT3952858T (https=)
RS (1) RS67777B1 (https=)
SG (1) SG11202110599RA (https=)
SI (1) SI3952858T1 (https=)
SM (1) SMT202600066T1 (https=)
UA (1) UA129840C2 (https=)
WO (1) WO2020206504A1 (https=)
ZA (1) ZA202108677B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597019A (en) * 2005-12-23 2013-11-29 Qbiotics Ltd Tiglien-3-one derivatives
JP7013753B2 (ja) * 2017-09-15 2022-02-01 株式会社三洋物産 遊技機
IL289072B2 (en) 2019-06-19 2025-06-01 QBiotics Pty Ltd Biofilm disruption
JP2024546296A (ja) * 2021-12-21 2024-12-19 キューバイオティクス プロプライアタリー リミティド 結晶性中間体
CN120569368A (zh) * 2022-12-21 2025-08-29 Q生物股份有限公司 晶型及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597019A (en) * 2005-12-23 2013-11-29 Qbiotics Ltd Tiglien-3-one derivatives
UA118670C2 (uk) * 2013-04-18 2019-02-25 К'Юбайотікс Лімітед Способи та композиції для загоєння ран
JP2019523303A (ja) * 2016-07-28 2019-08-22 キューバイオティクス リミティド 治療方法
CN110461324A (zh) 2017-03-23 2019-11-15 Q生物股份有限公司 用于治疗或预防肿瘤的联合疗法

Also Published As

Publication number Publication date
LT3952858T (lt) 2026-04-10
US20220193023A1 (en) 2022-06-23
IL287210B2 (en) 2025-07-01
AU2020256847A1 (en) 2021-11-11
PT3952858T (pt) 2026-02-26
IL287210B1 (en) 2025-03-01
SG11202110599RA (en) 2021-10-28
CA3136216A1 (en) 2020-10-15
CN113924091A (zh) 2022-01-11
EP3952858A1 (en) 2022-02-16
EP3952858B1 (en) 2025-12-17
ES3063750T3 (en) 2026-04-20
WO2020206504A1 (en) 2020-10-15
SMT202600066T1 (it) 2026-03-09
JP2022528915A (ja) 2022-06-16
ZA202108677B (en) 2026-03-25
AU2020256847B2 (en) 2025-05-15
IL287210A (en) 2021-12-01
US12226391B2 (en) 2025-02-18
DK3952858T3 (da) 2026-02-23
RS67777B1 (sr) 2026-03-31
JP2025060945A (ja) 2025-04-10
MY208979A (en) 2025-06-14
HRP20260232T1 (hr) 2026-03-27
PL3952858T3 (pl) 2026-03-30
EA202192757A1 (ru) 2022-02-11
FI3952858T3 (fi) 2026-02-18
MX2021012449A (es) 2021-11-12
EP3952858A4 (en) 2022-05-25
KR20210152531A (ko) 2021-12-15
UA129840C2 (uk) 2025-08-20
BR112021020253A2 (pt) 2021-12-07
SI3952858T1 (sl) 2026-04-30

Similar Documents

Publication Publication Date Title
CA3136216C (en) Method of treating tumours
ES2953575T3 (es) Terapia de combinación para el tratamiento o la prevención de tumores
US20250134847A1 (en) Combination therapies
HK40060616A (en) Method of treating tumours
HK40060616B (en) Method of treating tumours
EA044461B1 (ru) Способ лечения опухолей
EA044756B1 (ru) Комбинированная терапия для лечения или предупреждения опухолей
BR112019019748B1 (pt) Usos de um composto de epóxitigliano ou um sal farmaceuticamente aceitável do mesmo, usos de um inibidor do ponto de verificação imunológico e kit

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220310

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250516

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260331

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260331